Jyong Biotech (NASDAQ:MENS) Shares Gap Down – Here’s What Happened

Shares of Jyong Biotech Ltd. (NASDAQ:MENS) gapped down prior to trading on Friday . The stock had previously closed at $29.19, but opened at $28.10. Jyong Biotech shares last traded at $29.01, with a volume of 946 shares trading hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jyong Biotech in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Jyong Biotech Stock Performance

The company’s 50 day simple moving average is $44.02.

Institutional Investors Weigh In On Jyong Biotech

An institutional investor recently bought a new position in Jyong Biotech stock. BNP Paribas Financial Markets purchased a new position in shares of Jyong Biotech Ltd. (NASDAQ:MENS) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 1,698 shares of the company’s stock, valued at approximately $67,000.

About Jyong Biotech

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.